The company said this further contributes to its growth and brand expansion initiatives strategy for 2021, with Harvest One continuing to focus on the.
Aequus Pharmaceuticals says it will maintain commercial relationship with Sandoz into 2022
There is potential to extend the current partnership beyond February 2022 and expand to include additional products beyond Vistitan and Tacrolimus IR Aequus is a growing specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products
Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) will maintain its current commercial relationship pertaining to the Vistitan glaucoma drug, with Sandoz into 2022.
As a specialty pharmaceutical company, Aequus Pharmaceuticals is focused on developing, advancing and promoting differentiated products. The product line includes several medications for eye health as well as an anti-rejection drug (Tacrolimus IR) for transplant recipients.